Glioma proliferation as assessed by 3′-fluoro-3′-deoxy-L- thymidine positron emission tomography in patients with newly diagnosed high-grade glioma

Clinical Cancer Research

Volumn 14, Issue 7, 2008, Pages 2049-2055

  Ullrich, Roland ^a,b   Backes, Heiko ^b   Li, Hongfeng ^a   Kracht, Lutz ^a   Miletic, Hrvoje ^b   Kesper, Kristina ^a   Neumaier, Bernd ^a   Heiss, Wolf Dieter ^a   Wienhard, Klaus ^a   Jacobs, Andreas H ^a,b,c  

^a MAX PLANCK INSTITUTE FOR NEUROLOGICAL RESEARCH   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c KLINIKUM FULDA   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

3' FLUOROTHYMIDINE F18; KI 67 ANTIGEN; METHYLMETHIONINE C11; TRACER; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; ASTROCYTOMA; BLOOD BRAIN BARRIER; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GLIOMA; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LINEAR REGRESSION ANALYSIS; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

ADULT; AGED; BRAIN NEOPLASMS; CARBON RADIOISOTOPES; CELL PROLIFERATION; DIDEOXYNUCLEOSIDES; FEMALE; FLUORINE RADIOISOTOPES; GLIOMA; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MAGNETIC RESONANCE IMAGING; MALE; METHIONINE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION;

EID: 42249098076     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-1553     Document Type: Article

References (30)

1. Jacobs AH, Dittmar C, Winkeler A, Garlip G, Heiss WD. Molecular imaging of gliomas. Mol Imaging 2002;1:309-35.
2. Kracht LW, Friese M, Herholz K, et al. Methyl-[11C]-l-methionine uptake as measured by positron emission tomography correlates to microvessel density in patients with glioma. Eur J Nucl Med Mol Imaging 2003;30:868-73.
3. Sato N, Suzuki M, Kuwata N, et al. Evaluation of the malignancy of glioma using 11C-methionine positron emission tomography and proliferating cell nuclear antigen staining. Neurosurg Rev1999;22:210-4.
4. Miyagawa T, Oku T, Uehara H, et al. "Facilitated" amino acid transport is upregulated in brain tumors. J Cereb Blood Flow Metab 1998;18:500-9.
5. Shields AF, Grierson JR, Dohmen BM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 1998;4:1334-6.
6. Sherley JL, Kelly TJ. Regulation of human thymidine kinase during the cell cycle. J Biol Chem 1988;263:8350-8.
7. Toyohara J, Waki A, Takamatsu S, Yonekura Y, Magata Y, Fujibayashi Y. Basis of FLT as a cell proliferation marker: comparative uptake studies with [3H]thymidine and [3H]arabinothymidine, and cell-analysis in 22 asynchronously growing tumor cell lines. Nucl Med Biol 2002;29:281-7.
8. Wells P, Gunn RN, Alison M, et al. Assessment of proliferation in vivo using 2-[(11)C]thymidine positron emission tomography in advanced intra-abdominal malignancies. Cancer Res 2002;62:5698-702.
9. Vesselle H, Grierson J, Muzi M, et al. In vivo validation of 3′deoxy-3′-[(18)F]fluorothymidine ([(18)F]FLT) as a proliferation imaging tracer in humans: correlation of [(18)F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors. Clin Cancer Res 2002;8:3315-23.
10. Buck AK, Bommer M, Stilgenbauer S, et al. Molecular imaging of proliferation in malignant lymphoma. Cancer Res 2006;66:11055-61.
11. Buck AK, Halter G, Schirrmeister H, et al. Imaging proliferation in lung tumors with PET:18F-FLT versus 18F-FDG. J Nucl Med 2003;44:1426-31.
12. Francis DL, Visvikis D, Costa DC, et al. Potential impact of [18F]3′-deoxy-3′-fluorothymidine versus [18F]fluoro-2-deoxy- D-glucose in positron emission tomography for colorectal cancer. Eur J Nucl Med Mol Imaging 2003;30:988-94.
13. Buck AK, Schirrmeister H, Hetzel M, et al. 3-deoxy-3-[(18)F] fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules. Cancer Res 2002;62:3331-4.
14. Wagner M, Seitz U, Buck A, et al. 3′-[18F]fluoro-3′- deoxythymidine ([18F]-FLT) as positron emission tomography tracer for imaging proliferation in a murine B-Cell lymphoma model and in the human disease. Cancer Res 2003;63:2681-7.
15. Chen W, Cloughesy T, Kamdar N, et al. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG. J Nucl Med 2005;46:945- 52.
16. Jacobs AH, Thomas A, Kracht LW, et al.18F-fluoro-L-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in brain tumors. J Nucl Med 2005;46:1948-58.
17. Muzi M, Spence AM, O'Sullivan F, et al. Kinetic analysis of 3′-deoxy-3′-18F-fluorothymidine in patients with gliomas. J Nucl Med 2006;47:1612-21.
18. Cizek J, Herholz K, Vollmar S, Schrader R, Klein J, Heiss WD. Fast and robust registration of PET and MR images of human brain. Neuroimage 2004;22:434-42.
19. Vollmar S CJ, Sue M, Klein J, Jacobs AH, Herholz K. VINCI - Volume Imaging in Neurological Research, Co-Registration and ROIs Forschung und wissenschaftliches Rechnen 2003. In: Kremer K, Macho V, editors. Göttingen: Gesellschaft für wissenschaftliche Datenverarbeitung; 2004. p.115-31.
20. Mankoff DA, Shields AF, Graham MM, Link JM, Eary JF, Krohn KA. Kinetic analysis of 2-[carbon-11]thymidine PET imaging studies: compartmental model and mathematical analysis. J Nucl Med 1998;39:1043-55.
21. Mankoff DA, Shields AF, Link JM, et al. Kinetic analysis of 2-[11C]thymidine PET imaging studies: validation studies. J Nucl Med 1999;40:614-24.
22. Muzi M, Vesselle H, Grierson JR, et al. Kinetic analysis of 3′-deoxy-3′-fluorothymidine PET studies: validation studies in patients with lung cancer. J Nucl Med 2005;46:274-82.
23. Krohn KA, Mankoff DA, Muzi M, Link JM, Spence AM. True tracers: comparing FDG with glucose and FLT with thymidine. Nucl Med Biol 2005;32:663-71.
24. Patlak CS, Blasberg RG. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations. J Cereb Blood Flow Metab 1985;5:584-90.
25. Spence AM, Muzi M, Graham MM, et al. Glucose metabolism in human malignant gliomas measured quantitatively with PET, 1-[C-11]glucose and FDG: analysis of the FDG lumped constant. J Nucl Med 1998;39:440 - 8.
26. Kracht LW, Miletic H, Busch S, et al. Delineation of brain tumor extent with [11C] L-methionine positron emission tomography: local comparison with stereotactic histopathology. Clin Cancer Res 2004;10:7163-70.
27. Rasey JS, Grierson JR, Wiens LW, Kolb PD, Schwartz JL. Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med 2002;43:1210-7.
28. Barthel H, Perumal M, Latigo J, et al. The uptake of 3′-deoxy- 3′-[18F]fluorothymidine into L5178Y tumours in vivo is dependent on thymidine kinase 1 protein levels. Eur J Nucl Med Mol Imaging 2005;32:257-63.
29. Grierson JR, Schwartz JL, Muzi M, Jordan R, Krohn KA. Metabolism of 3′-deoxy-3′-[F-18]fluorothymidine in proliferating A549 cells: validations for positron emission tomography. Nucl Med Biol 2004;31:829-37.
30. Wells JM, Mankoff DA, Eary JF, et al. Kinetic analysis of 2-[11C]thymidine PET imaging studies of malignant brain tumors: preliminary patient results. Mol Imaging 2002;1:145-50.